Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue.Effective treatments are needed for patients with muscle-invasive bladder cancer scheduled for radical cystectomy who are ineligible for or decline to receive neoadjuvant cisplatin-based chemotherapy. SunRISe-4 is a randomised, open-label, phase 2 trial being conducted at 109 investigative centres in ten countries worldwide, and aims to evaluate the safety and efficacy of neoadjuvant TAR-200 plus cetrelimab (anti-PD-1) versus cetrelimab monotherapy in this disease setting.They discuss the unique features of the TAR-200 localised sustained delivery system for gemcitabine, the key findings from the SunRISe4-trial trial, and what the future implications of the findings are in terms of better treatment options for patients with bladder cancer.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00358-4/abstract?dgcid=buzzsprout_icw_podcast_September_25_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Ver todos los episodios